BackInfinity Pharmaceuticals Overview

Infinity Pharmaceuticals Net Tangible Assets

Infinity Pharmaceuticals's net tangible assets is $-37M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-37.41M
3279.04% YoYΔ $-36.30M vs prior year quarter

Peer average / median

Loading

Infinity Pharmaceuticals Net Tangible Assets History

Loading

Infinity Pharmaceuticals vs. peers: Net Tangible Assets Comparison

Loading

Infinity Pharmaceuticals Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Infinity Pharmaceuticals (INFI) FAQ

Infinity Pharmaceuticals's net tangible assets stands at $-37M as of June 2023. That compares with $-1.1M in the prior-year period — down 3279.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Infinity Pharmaceuticals reported $-37M in net tangible assets versus $-1.1M a year earlier — a 3279.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-1.1M in the prior-year period — down 3279.0% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Infinity Pharmaceuticals's net tangible assets evolved across reporting periods, while the comparison chart places INFI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Infinity Pharmaceuticals's reading of $-37M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.